222164-34-3

Upstream product

• 123565-82-2 ethyl 5-cyano-1-(4-methoxyphenyl)-4-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate 
• 18794-95-1 3-oxo-2-(2-(4-methoxyphenyl)hydrazono)butanoic acid ethyl ester 
• 104-94-9 4-methoxy-aniline 
• 123542-48-3 ethyl 5-amino-3,4-dihydro-3-(4-methoxyphenyl)-4-oxothieno<3,4-d>pyridazine-1-carboxylate 

Downstream Products

• 1443744-62-4 C₁₉H₂₁⁽¹⁸⁾FN₄O₃S 
• 1443744-63-5 C₁₈H₁₉⁽¹⁸⁾FN₄O₃S 
• 1443745-59-2 C₂₂H₂₆N₄O₆S₂ 
• 1282449-15-3 5-amino-3-(4-hydroxyphenyl)-N-isopropyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide 
• 1443744-65-7 C₁₉H₂₁FN₄O₄S 
• 1443745-60-5 C₁₉H₂₀N₄O₄S 
• 1443744-66-8 C₁₉H₂₁FN₄O₃S 
• 1443745-61-6 C₂₆H₂₈N₄O₆S₂ 
• 1443745-62-7 C₂₁H₂₄N₄O₅S 
• 1443744-67-9 C₂₃H₂₇FN₄O₅S 
• 1443745-65-0 C₂₅H₂₆N₄O₆S₂ 
• 1443829-61-5 C₂₀H₂₁FN₄O₃S 
• 1443744-64-6 C₂₁H₂₃FN₄O₃S 
• 1443744-68-0 C₂₃H₂₁FN₆O₃S 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY

Pyridazinone compounds of Formula I: (I) wherein: R' is alkyl or Ar, optionally substituted with at least one alkyl, halo? gen, hydroxyl, alkoxy, haloalkoxy, acid, ester, amino, nitro, amide, or alkoxyhalo; 2 R is independently alkyi, alkynyl, ester, amino, amide, acid, aryl, heteroaryl, aminoalkyl, -C(=0)alkyl, -C(=0)aryl, -C(=0)heteroaryl, -C(=0)heterocycloalkyl, - C(=0)heterocycloalkylAr, -C(=0)(CH2)nhalo, -C(=0)(CH2)nheterocyclyl, or -SC^Ar, optionally substituted with at least one alkyi, alkylhalo, halogen, nitro, aryl, heteroaryl, or heteroaryl(CH2)nhalo; R 3 and R4 are independently hydrogen, alkyi, alkenyl, alkynyl, aryl, heteroaryl; Ar is an aryl, heteroaryl, cycloalkyl, heterocycloalkyl group; n is an integer from 0-10; or a radiolabeled derivative thereof. The compounds are useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.

2-Aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists

A pharmacophore-based screen identified 32 compounds including ethyl 5-amino-3-(4-tert-butylphenyl)-4-oxo-3,4-dihydrothieno[3,4-d] pyridazine-1-carboxylate (8) as a new allosteric modulator of the adenosine A1 receptor (A1AR). On the basis of this lead, various derivatives were prepared and evaluated for activity at the human A 1AR. A number of the test compounds allosterically stabilized agonist-receptor-G protein ternary complexes in dissociation kinetic assays, but were found to be more potent as antagonists in subsequent functional assays of ERK1/2 phosphorylation. Additional experiments on the most potent antagonist, 13b, investigating A1AR-mediated [35S]GTPγS binding and [3H]CCPA equilibrium binding confirmed its antagonistic mode of action and also identified inverse agonism. This study has thus identified a new class of A1AR antagonists that can also recognize the receptor's allosteric site with lower potency.